Area of research
Molecular Biology · Infectious Diseases
Research interest
Research interests include vaccines and immunoinformatics approaches, Immunotherapy and Immune Responses, SARS-CoV-2 and COVID-19 Research, and Monoclonal and Polyclonal Antibodies Research.
Unveiling conserved HIV-1 open reading frames encoding T cell antigens using ribosome profiling
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells
Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo
Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies
HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation